Product Information
CARBIDOPA-LEVO ER 25-100 TAB is a generic product labeled by ScieGen Pharmaceuticals Inc., priced at $0.1137 per EA under NDC 50228046010. Its NADAC has been published 185 times since Feb 8, 2023.
FDA first approved this application on Oct 5, 2021. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
25; 100 mg/1; mg/1
Manufacturer
ScieGen Pharmaceuticals Inc.NDC
50228046010
Classification
Generic
Dosage Form
TABLET, EXTENDED RELEASE
Route
ORAL
Effective Date
8/19/2026
Active Ingredients
CARBIDOPA; LEVODOPAApproval Type
Generic (ANDA)
FDA Application
ANDA214091FDA Approved
10/5/2021
TE Code
AB
On Market Since
10/5/2021
Pharmacological Classes
Price Statistics
The NADAC for CARBIDOPA-LEVO ER 25-100 TAB has been published 185 times since Feb 8, 2023, and over the history we have for it it has declined 39.0%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1137 per EA |
|---|---|
| All-time high | $0.1865 (Feb 15, 2023) |
| All-time low | $0.1048 (Nov 20, 2024) |
| 52-week high | $0.1349 |
| 52-week low | $0.1101 |
| Median price | $0.1417 |
| Average price | $0.1392 |
| Largest weekly change | -27.5% (Nov 20, 2024) |
| Weeks tracked | 185 |
| Tracking since | Feb 8, 2023 |
Generic Alternatives
The matcher finds 9 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 33% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of CARBIDOPA-LEVO ER 25-100 TAB?
The current National Average Drug Acquisition Cost (NADAC) for CARBIDOPA-LEVO ER 25-100 TAB, manufactured by ScieGen Pharmaceuticals Inc., is $0.1137 per EA (NDC 50228046010), effective Aug 19, 2026.
How has the price of CARBIDOPA-LEVO ER 25-100 TAB changed over time?
Over the history we have for it, the NADAC for CARBIDOPA-LEVO ER 25-100 TAB has declined 39.0%. It has been tracked across 185 weekly CMS publications since Feb 8, 2023.
What are the highest and lowest recorded NADAC prices for CARBIDOPA-LEVO ER 25-100 TAB?
Since Feb 8, 2023, the NADAC for CARBIDOPA-LEVO ER 25-100 TAB has ranged from a low of $0.1048 (Nov 20, 2024) to a high of $0.1865 (Feb 15, 2023), with a median of $0.1417 per EA.
Are there cheaper alternatives to CARBIDOPA-LEVO ER 25-100 TAB?
Yes. 9 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, CARBIDOPA-LEVODOPA 25-100 TAB, is $0.0766 per EA — about 33% below CARBIDOPA-LEVO ER 25-100 TAB.
Who manufactures CARBIDOPA-LEVO ER 25-100 TAB?
CARBIDOPA-LEVO ER 25-100 TAB (NDC 50228046010) is labeled by ScieGen Pharmaceuticals Inc., and CMS classifies it as a generic product.